These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 38720450)
1. External validation of models to predict hepatocellular carcinoma in Hepatitis C Virus cured F3-F4 patients. Carvalho-Gomes Â; Valcheva Valcheva TV; Sahuco I; Vidal E; Martínez-Arenas L; Vinaixa C; Aguilera V; García García S; Berenguer M United European Gastroenterol J; 2024 Sep; 12(7):901-910. PubMed ID: 38720450 [TBL] [Abstract][Full Text] [Related]
2. Prediction of Hepatocellular Carcinoma Development in Korean Patients after Hepatitis C Cure with Direct-Acting Antivirals. Hong H; Choi WM; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Choi J Gut Liver; 2024 Jan; 18(1):147-155. PubMed ID: 37076993 [TBL] [Abstract][Full Text] [Related]
3. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095 [TBL] [Abstract][Full Text] [Related]
4. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707 [TBL] [Abstract][Full Text] [Related]
5. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. Semmler G; Meyer EL; Kozbial K; Schwabl P; Hametner-Schreil S; Zanetto A; Bauer D; Chromy D; Simbrunner B; Scheiner B; Stättermayer AF; Pinter M; Schöfl R; Russo FP; Greenfield H; Schwarz M; Schwarz C; Gschwantler M; Alonso López S; Manzano ML; Ahumada A; Bañares R; Pons M; Rodríguez-Tajes S; Genescà J; Lens S; Trauner M; Ferenci P; Reiberger T; Mandorfer M J Hepatol; 2022 Apr; 76(4):812-821. PubMed ID: 34871626 [TBL] [Abstract][Full Text] [Related]
7. Predictive models for hepatocellular carcinoma development after sustained virological response in advanced hepatitis C. Fraile-López M; Alvarez-Navascués C; González-Diéguez ML; Cadahía V; Chiminazzo V; Castaño A; Varela M; Rodríguez M Gastroenterol Hepatol; 2023 Dec; 46(10):754-763. PubMed ID: 36716928 [TBL] [Abstract][Full Text] [Related]
8. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis. Alonso López S; Manzano ML; Gea F; Gutiérrez ML; Ahumada AM; Devesa MJ; Olveira A; Polo BA; Márquez L; Fernández I; Cobo JCR; Rayón L; Riado D; Izquierdo S; Usón C; Real Y; Rincón D; Fernández-Rodríguez CM; Bañares R Hepatology; 2020 Dec; 72(6):1924-1934. PubMed ID: 33022803 [TBL] [Abstract][Full Text] [Related]
9. Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs. Søholm J; Hansen JF; Mössner B; Røge BT; Lauersen A; Hansen JB; Weis N; Barfod TS; Lunding S; Øvrehus A; Mohey R; Thielsen P; Christensen PB PLoS One; 2020; 15(12):e0243725. PubMed ID: 33301499 [TBL] [Abstract][Full Text] [Related]
10. Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma. Toyoda H; Tada T; Uojima H; Nozaki A; Chuma M; Takaguchi K; Hiraoka A; Abe H; Itobayashi E; Matsuura K; Atsukawa M; Watanabe T; Shimada N; Nakamuta M; Kojima M; Tsuji K; Mikami S; Ishikawa T; Yasuda S; Tsutsui A; Arai T; Kumada T; Tanaka Y; Tanaka J; Chayama K J Gastroenterol Hepatol; 2024 May; 39(5):949-954. PubMed ID: 38291715 [TBL] [Abstract][Full Text] [Related]
11. Comparison of acknowledged hepatocellular carcinoma risk scores in high-risk hepatitis C patients with sustained virological response. Qiu L; Xu S; Qiu Y; Liu Y; Zhang J J Viral Hepat; 2023 Jun; 30(6):559-566. PubMed ID: 36890735 [TBL] [Abstract][Full Text] [Related]
12. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. Ioannou GN; Green PK; Beste LA; Mun EJ; Kerr KF; Berry K J Hepatol; 2018 Nov; 69(5):1088-1098. PubMed ID: 30138686 [TBL] [Abstract][Full Text] [Related]
13. Comparing Predictability of Non-invasive Tools for Hepatocellular Carcinoma in Treated Chronic Hepatitis C Patients. Liu YC; Cheng YT; Chen YC; Hsieh YC; Jeng WJ; Lin CY; Chien RN; Tai DI; Sheen IS Dig Dis Sci; 2023 Jan; 68(1):323-332. PubMed ID: 35895234 [TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication. Vutien P; Kim NJ; Moon AM; Johnson KM; Berry K; Green PK; Ioannou GN Aliment Pharmacol Ther; 2024 Feb; 59(3):361-371. PubMed ID: 37955206 [TBL] [Abstract][Full Text] [Related]
15. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234 [TBL] [Abstract][Full Text] [Related]
16. Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C. Chun HS; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Lee CH; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH; Lee JH; Kim SU Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):378-385. PubMed ID: 32011388 [TBL] [Abstract][Full Text] [Related]
17. Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis. Kim NJ; Vutien P; Cleveland E; Cravero A; Ioannou GN Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1723-1738.e5. PubMed ID: 35525392 [TBL] [Abstract][Full Text] [Related]
18. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002 [TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma in patients cured of chronic hepatitis C: Minimal steatosis. Rocha C; Doyle EH; Bowman CA; Fiel MI; Stueck AE; Goossens N; Bichoupan K; Patel N; Crismale JF; Makkar J; Lewis S; Perumalswami PV; Schiano TD; Hoshida Y; Schwartz M; Branch AD Cancer Med; 2023 May; 12(9):10175-10186. PubMed ID: 37078924 [TBL] [Abstract][Full Text] [Related]
20. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V; Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]